Holen Sie sich die Stockscreener-App
73.57
0.77%
0.56
Handel nachbörslich:
73.57
Schlusskurs vom Vortag:
$73.01
Offen:
$73.15
24-Stunden-Volumen:
568.76K
Relative Volume:
0.50
Marktkapitalisierung:
$6.09B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
9.5096
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
+3.24%
1M Leistung:
+14.08%
6M Leistung:
+7.39%
1J Leistung:
+56.73%
1-Tages-Spanne:
$72.20
$73.69
1-Wochen-Bereich:
$68.22
$73.79
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
73.57 | 6.04B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Yousif Capital Management LLC Buys Shares of 22,228 PTC Therapeutics, Inc. $PTCT - MarketBeat
24,524 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Ritholtz Wealth Management - MarketBeat
Burney Co. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Raymond James Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $86 - Moomoo
Is It Time To Reassess PTC Therapeutics (PTCT) After Its Strong One Year Rally? - Sahm
PTCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
B of A Securities Lowers Price Target for PTC Therapeutics (PTCT) to $93 | PTCT Stock News - GuruFocus
(PTCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Raymond James Financial - MarketBeat
Treasury Yields: Will PTC Therapeutics Inc benefit from current market trends2026 Sector Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Raymond James Financial - MarketBeat
Is PTC Therapeutics Inc attractive for institutional investors2026 Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Raymond James initiates PTC Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa
Raymond James initiates PTC Therapeutics stock coverage with outperform rating - Investing.com
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,265 Shares - MarketBeat
PTC Therapeutics exec VP Boulding sells $157k in shares By Investing.com - Investing.com Canada
PTC Therapeutics (PTCT) EVP trades options and sells 2,265 shares - Stock Titan
RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating - Moomoo
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $81 - Moomoo
Duchenne Muscular Dystrophy Therapeutics Market to Reach USD - openPR.com
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells 829 Shares of Stock - MarketBeat
Golden Lee, PTC Therapeutics EVP, sells $56k in shares By Investing.com - Investing.com Canada
PTC Therapeutics (PTCT) CMO executes 829-share tax sell-to-cover - Stock Titan
PTCT (NASDAQ: PTCT) Form 144: Insider proposes sale of 2,265 shares - Stock Titan
PTCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PTC Therapeutics, Inc. (PTCT) stock price, news, quote and history - uk.finance.yahoo.com
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty - Yahoo Finance
How Investors Are Reacting To PTC Therapeutics (PTCT) Adding Veteran Dealmaker Jessica Chutter To Its Board - Sahm
Almstead, PTC Therapeutics officer, sells $3.59 million in shares By Investing.com - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 52,003 Shares - MarketBeat
PTC Therapeutics (PTCT) officer sells 52,003 shares under 10b5-1 plan - Stock Titan
PTCT (NASDAQ: PTCT) lists 829 vested shares for resale; insider sales detailed - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock forecasts - Yahoo Finance UK
Form 144 | PTC Therapeutics(PTCT.US) Officer Proposes to Sell 3.59 Million in Common Stocks - Moomoo
Insiders sell shares at PTCT (NASDAQ: PTCT) under Rule 144, multiple trades - Stock Titan
(PTCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jefferies Downgrades PTC Therapeutics (PTCT) to 'Hold' with Pric - GuruFocus
PTC Therapeutics Inc (PTCT) Stock Price Quote Today & Current Price Chart - Capital.com
PTC Therapeutics, Inc. (PTCT) Latest Stock News & Headlines - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Earns "Hold" Rating from Jefferies Financial Group - MarketBeat
Jefferies Initiates PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $76 - Moomoo
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Jefferies downgrades PTC Therapeutics (PTCT) - MSN
Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance? - Sahm
PTC Therapeutics Inc (PTCT) Stock Price, Trades & News - GuruFocus
Vanguard disaggregates holdings; reports 0 PTC Therapeutics shares (PTCT) - Stock Titan
PTC Therapeutics (PTCT) director receives new stock and option awards - Stock Titan
New PTC Therapeutics (PTCT) director Jessica Chutter files initial Form 3 - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Rating Updates Drive Nasdaq Futures Focus - Kalkine Media
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Truist Financial - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):